Article Sidebar
Published:
Feb 5, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of atorvastatin combined with interventional therapy for acute myocardial infarction
Abstract
Purpose: To evaluate the coronary thrombolytic effect of atorvastatin plus percutaneous coronary intervention (PCI) for the treatment of acute myocardial infarction.
Methods: From April 2019 to October 2020, 88 patients with acute myocardial infarction who were treated in Zhangqiu District People's Hospital were randomly assigned to receive either PCI (conventional group) or PCI plus atorvastatin (combined group). Myocardial injury index, TnI, and creatine kinase isoenzyme (CK-MB) were used to determine myocardial injury, while serum cTnI was determined using enzyme-linked immunosorbent assay (ELISA). Creatine kinase isoenzyme (CK-MB) levels were determined by immunosuppression method. Cardiac ultrasound was used to measure and compare the left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), and left ventricular end-systolic diameter (LVESD) before and after treatment in the two groups. Blood lipid levels were determined before and after drug administration, respectively, while the levels of highdensity lipoprotein cholesterol (HDL-C) were determined using a colorimetric method. Total cholesterol (TC) and triacylglycerol (TG) were assessed by an enzymatic method, while low-density lipoprotein cholesterol (LDL-C) was determined using a biochemical method. Serum B-type natriuretic peptide (BNP), c-reactive-protein (CRP), and interleukin (IL)-6 levels were evaluated in an automatic biochemical analyzer. The incidence of adverse reactions during treatment, including creatinine elevation, muscle pain, and gastrointestinal reactions and their frequencies were computed.
Results: The combined group exhibited significantly lower levels of myocardial injury indices when compared with the conventional group (p < 0.05). Atorvastatin plus PCI resulted in significantly higher left ventricular ejection fraction (LVEF), and lower left ventricular end-diastolic dimension (LVEDD) as well as left ventricular end-systolic diameter (LVESD) in patients when compared with PCI alone group (p < 0.05). After treatment, the combined group showed significantly healthier levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) compared with the conventional group (p < 0.05).
Conclusion: Atorvastatin plus PCI mitigates myocardial injury and lowers cardiac function, lipid indices, serum B type natriuretic peptide (BNP), C-reactive-protein (CRP), and interleukin (IL)-6 levels. It also reduces the incidence of adverse events during treatment. Thus, this therapeutic strategy has potentials for application in the management of acute myocardial infarction.
